{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T19:20:52Z","timestamp":1777749652189,"version":"3.51.4"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["308521\/2017-0"],"award-info":[{"award-number":["308521\/2017-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["301560\/2018-8"],"award-info":[{"award-number":["301560\/2018-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2018\/17480-9"],"award-info":[{"award-number":["2018\/17480-9"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2018\/08585-1"],"award-info":[{"award-number":["2018\/08585-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2013\/27186-7"],"award-info":[{"award-number":["2013\/27186-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2015\/07893-6"],"award-info":[{"award-number":["2015\/07893-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.bioorg.2021.104982","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T22:24:30Z","timestamp":1620685470000},"page":"104982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Synthesis, biological evaluation and molecular docking studies of novel 1,2,3-triazole-quinazolines as antiproliferative agents displaying ERK inhibitory activity"],"prefix":"10.1016","volume":"113","author":[{"given":"Paulo S\u00e9rgio Gon\u00e7alves","family":"Nunes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susimaire Pedersoli","family":"Mantoani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peterson","family":"de Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emerson Soares","family":"Bernardes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F\u00e1bio","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreia Machado","family":"Leopoldino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivone","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2021.104982_b0005","doi-asserted-by":"crossref","unstructured":"F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 68 (2018) 394-424. http:\/\/dx.doi.10.3322\/caac.21492.","DOI":"10.3322\/caac.21492"},{"key":"10.1016\/j.bioorg.2021.104982_b0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1146\/annurev-cancerbio-030419-033612","article-title":"Metabolic Drivers in Hereditary Cancer Syndromes","volume":"4","author":"Sciacovelli","year":"2020","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.bioorg.2021.104982_b0015","doi-asserted-by":"crossref","first-page":"236","DOI":"10.7326\/M15-0754","article-title":"The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model","volume":"164","author":"Birnbaum","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bioorg.2021.104982_b0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc.2015.18","article-title":"The kinome 'at large' in cancer","volume":"16","author":"Fleuren","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2021.104982_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2021.104982_b0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.bioorg.2021.104982_b0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting Alterations in the RAF-MEK Pathway","volume":"9","author":"Yaeger","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2021.104982_b0040","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41416-019-0499-1","article-title":"Direct Ras G12C inhibitors: crossing the rubicon","volume":"121","author":"Lindsay","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2021.104982_b0045","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nrc.2017.79","article-title":"New perspectives for targeting RAF kinase in human c\u00e2ncer","volume":"17","author":"Karoulia","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2021.104982_b0050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2021.104982_b0055","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-class ERK1\/2 Inhibitor Ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a Phase I dose-escalation and expansion study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2021.104982_b0060","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40265-018-0884-8","article-title":"BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers","volume":"78","author":"Sanchez","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2021.104982_b0065","unstructured":"S. Saha, D. Welsch, G. DeCrescenzo, J.J. Roix. US 20160317519 A1, 2016."},{"key":"10.1016\/j.bioorg.2021.104982_b0070","first-page":"761","article-title":"MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology, ACS Med","volume":"9","author":"Boga","year":"2018","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bioorg.2021.104982_b0075","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/2159-8290.CD-13-0070","article-title":"Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors","volume":"3","author":"Morris","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2021.104982_b0080","doi-asserted-by":"crossref","unstructured":"S.J. Moschos, R.J. Sullivan, W.-J. Hwu, R.K. Ramanathan, A.A. Adjei, P.C. Fong, R. Shapira-Frommer, H.A. Tawbi, J. Rubino, T.S. Rush III, D. Zhang, N.R. Miselis, A.A. Samatar, P. Chun, E.H. Rubin, J. Schiller, B.J. Long, P. Dayananth, D. Carr, P. Kirschmeier, W. Robert Bishop, Y. Deng, A. Cooper, G.W. Shipps, B.H. Moreno, L. Robert, A. Ribas, K.T. Flaherty. Development of MK-8353, an orally administered ERK1\/2 inhibitor, in patients with advanced solid tumors, JCI Insight, 3 (2018) e92352. http:\/\/dx.doi.10.1172.jci.insight.92352.","DOI":"10.1172\/jci.insight.92352"},{"key":"10.1016\/j.bioorg.2021.104982_b0085","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1016\/j.bmcl.2015.08.048","article-title":"Fragment-based discovery of potent ERK2 pyrrolopyrazine inhibitors","volume":"25","author":"Burdick","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2021.104982_b0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.02.007","article-title":"ERK1\/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1\/2-ERK1\/2 pathway","volume":"187","author":"Kidger","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2021.104982_b0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1073\/pnas.1313733111","article-title":"Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance","volume":"111","author":"Schwartz","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.bioorg.2021.104982_b0100","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s10637-013-9923-1","article-title":"Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA","volume":"31","author":"Marchetti","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bioorg.2021.104982_b0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejmech.2019.03.004","article-title":"Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry","volume":"170","author":"Das","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104982_b0110","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1021\/jm101150b","article-title":"Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2","volume":"54","author":"Caldwell","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104982_b0115","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/bjc.2011.21","article-title":"Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer","volume":"104","author":"Azzariti","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2021.104982_b0120","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1158\/1078-0432.CCR-06-2979","article-title":"AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis","volume":"13","author":"Wilkinson","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2021.104982_b0125","doi-asserted-by":"crossref","unstructured":"G.F. Smith, M.D. Altman, B. Andresen, J. Baker, J.D. Brubaker, H. Chen, Y. Chen, M. Childers, A. Donofrio, H. Ferguson, C. Fischer, T.O. Fischmann, C. Gibeau, A. Hicks, S. Jin, S. Kattar, M.A. Kleinschek, E. Leccese, C. Lesburg, C. Li, J. Lim, D. Liu, J.K.F. Maclean, F. Mansoor, L.Y. Moy, E.F. Mulrooney, A.S. Necheva, J. Presland, L. Rakhilin, R. Yang, L. Torres, J. Zhang-Hoover, A. Northrup, Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation, Bioorg. Med. Chem. Lett. 27 (2017) 2721\u20132726. http:\/\/dx.doi.10.1016\/j.bmcl.2017.04.050.","DOI":"10.1016\/j.bmcl.2017.04.050"},{"key":"10.1016\/j.bioorg.2021.104982_b0130","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.bmcl.2014.09.039","article-title":"Discovery of substituted 4-aminoquinazolines as selective Toll-like receptor 4 ligands","volume":"24","author":"Nour","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2021.104982_b0135","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.2174\/1385272822666181008142138","article-title":"Anti-cancer Nitrogen-Containing Heterocyclic Compounds","volume":"22","author":"Hosseinzadeh","year":"2018","journal-title":"Curr. Org. Chem."},{"key":"10.1016\/j.bioorg.2021.104982_b0140","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/bph.13096","article-title":"Ten things you should know about protein kinases: IUPHAR Review 14","volume":"172","author":"Fabbro","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2021.104982_b0145","doi-asserted-by":"crossref","first-page":"9475","DOI":"10.1016\/j.tet.2010.10.001","article-title":"Application of copper(I)-catalysed azide\/alkyne cycloaddition (CuAAC) \u2018click chemistry\u2019 in carbohydrate drug and neoglycopolymer synthesis","volume":"66","author":"Arag\u00e3o-Leoneti","year":"2010","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bioorg.2021.104982_b0150","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.bmc.2018.12.030","article-title":"Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease","volume":"27","author":"de Andrade","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104982_b0155","article-title":"Non-cytotoxic 1,2,3-triazole tethered fused heterocyclic ring derivatives display Tax protein inhibition and impair HTLV-1 infected cells","volume":"28","author":"Santos","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104982_b0160","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1016\/S0040-4039(02)00619-6","article-title":"Microwave-assisted Niementowski reaction. Back to the roots","volume":"43","author":"Alexandre","year":"2002","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.bioorg.2021.104982_b0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3998\/ark.5550190.0009.205","article-title":"One-pot reductive cyclization to antitumor quinazoline precursors","volume":"2008","author":"Kundu","year":"2008","journal-title":"Arkivoc"},{"key":"10.1016\/j.bioorg.2021.104982_b0170","first-page":"1269","article-title":"A simple and highly efficient process for synthesis of gefitinib and its intermediate","volume":"53B","author":"Kumar","year":"2014","journal-title":"Indian J. Chem. B."},{"key":"10.1016\/j.bioorg.2021.104982_b0175","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1021\/np50045a010","article-title":"Synthesis of Pratorimine","volume":"49","author":"Joshi","year":"1986","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2021.104982_b0180","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1021\/jm2001508","article-title":"Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia","volume":"54","author":"Helal","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104982_b0185","unstructured":"H.K. Gibson, Quinazoline Derivatives. PCT Int. Appl. WO 199633980, European Patent Office, 31 October 1996."},{"key":"10.1016\/j.bioorg.2021.104982_b0190","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1021\/ol060815y","article-title":"An efficient direct amination of cyclic amides and cyclic ureas","volume":"8","author":"Wan","year":"2006","journal-title":"Org. Lett."},{"key":"10.1016\/j.bioorg.2021.104982_b0195","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1021\/jm5001453","article-title":"Synthesis and structure-activity relationship studies of conformationally flexible tetrahydroisoquinolinyl triazole carboxamide and triazole substituted benzamide analogues as sigma2 receptor ligands","volume":"57","author":"Bai","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104982_b0200","doi-asserted-by":"crossref","unstructured":"D. Rodr\u00edguez-Hernandez, A.J. Demuner, L.C.A. Barbosa, L. Heller, R. CSUK. Novel hederagenin\u2013triazolyl derivatives as potential anti-cancer agents, Eur. J. Med. Chem. 115 (2016) 257\u2013267. http:\/\/dx.doi.10.1016\/j.ejmech.2016.03.018.","DOI":"10.1016\/j.ejmech.2016.03.018"},{"key":"10.1016\/j.bioorg.2021.104982_b0205","doi-asserted-by":"crossref","first-page":"9588","DOI":"10.1021\/ja0302836","article-title":"A potent and highly selective inhibitor of human alpha-1,3-fucosyltransferase via click chemistry","volume":"125","author":"Lee","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2021.104982_b0210","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/ejoc.201501301","article-title":"Copper Acetate Catalyzed Regio\u00adselective Synthesis of Substituted 1,2,3-Triazoles: A Versatile Azide\u2013Alk\u00adene Cycloaddition\/Oxidation Approach","author":"Rohilla","year":"2016","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.bioorg.2021.104982_b0215","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.bmc.2009.01.013","article-title":"Synthesis and in vitro antitubercular activity of a series of quinoline derivatives","volume":"17","author":"Souza","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104982_b0220","doi-asserted-by":"crossref","unstructured":"S.F.P. Braga, L.C.M., E.B. da Silva, P.A. Sales Jr, S.M.F. Murta, A.J. Romanha, W.T. Soh, H. Brandstetter, R.S. Ferreira, R.B. de Oliveira. Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification, Bioorg. Med. Chem. 25(6) (2017) 1889\u20131900. http:\/\/dx.doi.10.1016\/j.bmc.2017.02.009.","DOI":"10.1016\/j.bmc.2017.02.009"},{"key":"10.1016\/j.bioorg.2021.104982_b0225","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1021\/jm100639f","article-title":"Design, Synthesis, and Structure\u2212Affinity Relationships of Regioisomeric N-Benzyl Alkyl Ether Piperazine Derivatives as \u03c3-1 Receptor Ligands","volume":"53","author":"Moussa","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104982_b0230","doi-asserted-by":"crossref","first-page":"11511","DOI":"10.1002\/anie.201104735","article-title":"Amination of benzoxazoles and 1,3,4-oxadiazoles using 2,2,6,6-tetramethylpiperidine-N-oxoammonium tetrafluoroborate as an organic oxidant","volume":"50","author":"Wertz","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bioorg.2021.104982_b0235","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1021\/jm9016976","article-title":"Characterization of Tunable Piperidine and Piperazine Carbamates as Inhibitors of Endocannabinoid Hydrolases","volume":"53","author":"Long","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104982_b0240","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejmech.2011.01.020","article-title":"Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors","volume":"46","author":"Zhang","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104982_b0245","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1021\/ci700404c","article-title":"Combinatorial QSAR Modeling of Specificity and Subtype Selectivity of Ligands Binding to Serotonin Receptors 5HT1E and 5HT1F","volume":"48","author":"Wang","year":"2008","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2021.104982_b0250","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1038\/s41598-020-62848-5","article-title":"Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens","volume":"10","author":"Larsson","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2021.104982_b0255","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1038\/jid.2015.253","article-title":"Playing Polo-Like Kinase in NRAS-Mutant Melanoma","volume":"135","author":"Chen","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.bioorg.2021.104982_b0260","doi-asserted-by":"crossref","first-page":"517","DOI":"10.21873\/cgp.20208","article-title":"Combination of ERK2 and STAT3 Inhibitors Promotes Anticancer Effects on Acute Lymphoblastic Leukemia Cells","volume":"17","author":"Jasek-Gajda","year":"2020","journal-title":"Cancer Genom. Proteomics"},{"key":"10.1016\/j.bioorg.2021.104982_b0265","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2021.104982_b0270","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.cub.2006.04.044","article-title":"Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression","volume":"16","author":"Yamamoto","year":"2006","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bioorg.2021.104982_b0275","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1038\/sj.onc.1210414","article-title":"The ERK1\/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition","volume":"26","author":"Meloche","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2021.104982_b0280","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-020-0527-z","article-title":"Role of STAT3 signaling pathway in breast cancer","volume":"18","author":"Ma","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.bioorg.2021.104982_b0285","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11010-015-2509-9","article-title":"Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-\u03baB signaling in doxorubicin-resistant human breast carcinoma (MCF7\/ADR) cells","volume":"409","author":"Ku","year":"2015","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bioorg.2021.104982_b0290","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.bbamcr.2006.11.010","article-title":"ERK implication in cell cycle regulation","volume":"1773","author":"Chambard","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioorg.2021.104982_b0295","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.onc.1202367","article-title":"Constitutive activation of the 41-\/43-kDa mitogen-activated protein kinase signaling pathway in human tumors","volume":"18","author":"Hoshino","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2021.104982_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2019.129448","article-title":"Structural basis for the design of allosteric inhibitors of the Aurora kinase A enzyme in the cancer chemotherapy","volume":"1864","author":"Souza","year":"2020","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.bioorg.2021.104982_b0305","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1758-2946-2-S1-P50","article-title":"PoseView - molecular interaction patterns at a glance","volume":"2","author":"Stierand","year":"2010","journal-title":"J. Cheminform."},{"key":"10.1016\/j.bioorg.2021.104982_b0310","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00228-004-0877-2","article-title":"Co-prescription of cytochrome P450 2D6\/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies","volume":"61","author":"Molden","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bioorg.2021.104982_b0315","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/jssc.201901139","article-title":"Pharmacokinetics and metabolism of ulixertinib in rat by liquid chromatography combined with electrospray ionization tandem mass spectrometry","volume":"43","author":"Yu","year":"2020","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.bioorg.2021.104982_b0320","first-page":"328","article-title":"Review of PHYSPROP Database (Version 1.0)","volume":"35","author":"Bloch","year":"1995","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2021.104982_b0325","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1093\/carcin\/15.12.2683","article-title":"MTS1\/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma","volume":"15","author":"Yeudall","year":"1994","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bioorg.2021.104982_b0330","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejphar.2017.12.009","article-title":"Anti-cancer activity of a new dihydropyridine derivative, VdiE-2N, in head and neck squamous cell carcinoma","volume":"819","author":"Goto","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2021.104982_b0335","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2174\/1381612824666180515114236","article-title":"Biological and in silico studies on synthetic analogues of tyrosine betaine as inhibitors of neprilysin, a drug target for the treatment of heart failure","volume":"24","author":"Kawano","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bioorg.2021.104982_b0340","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s11030-017-9745-8","article-title":"Identification of a novel putative inhibitor of the Plasmodium falciparum purine nucleoside phosphorylase: exploring the purine salvage pathway to design new antimalarial drugs","volume":"21","author":"Kagami","year":"2017","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2021.104982_b0345","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1021\/ci700253h","article-title":"Lessons in Molecular Recognition 2: Assessing and Improving Cross-Docking Accuracy","volume":"47","author":"Sutherland","year":"2007","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2021.104982_b0350","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682100359X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682100359X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:52:51Z","timestamp":1777463571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682100359X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":70,"alternative-id":["S004520682100359X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.104982","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, biological evaluation and molecular docking studies of novel 1,2,3-triazole-quinazolines as antiproliferative agents displaying ERK inhibitory activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.104982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104982"}}